Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Cancer Biology;  Pathology/Molecular Biology;  Translational Research

Tumour Site

Head and Neck Cancers

Presenters

Hao-Wen Chuang

Citation

Annals of Oncology (2022) 33 (suppl_9): S1521-S1529. 10.1016/annonc/annonc1128

Authors

H. Chuang

Author affiliations

  • Pathology And Laboratory Medicine, Kaohsiung Veterans General Hospital, 81362 - Kaohsiung City/TW

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 240P

Background

This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).

Methods

We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.

Results

The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P

Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients

Parameters No. Mean ± SEM Median p
Agea
≤ 54 73 147.47 ± 7.77 160 0.132
> 54 49 163.83 ± 8.86 165
Gendera
Male 107 152.59 ± 6.45 160 0.561
Female 15 164.33 ± 13.21 160
Tumor siteb
Buccal 77 152.08 ± 7.29 160 0.700
Retromolar 24 148.96 ± 13.50 165
Tongue 7 170.36 ± 25.33 170
Others 14 165.36 ± 19.25 171
Histological gradeb
Well 45 149.00 ± 8.18 165 0.720
Moderate 71 156.13 ± 8.35 160
Poor 6 167.08 ± 30.81 183
Stagea
I–II 66 133.60 ± 7.41 153 <0.001*
III–IV 56 178.13 ± 8.34 184
Tumor statusa
T1–2 78 139.20 ± 7.18 160 <0.001*
T3–4 44 180.34 ± 8.98 186
Nodal metastasisa
Absent 91 145.36 ± 6.39 160 0.011*
Present 31 179.52 ± 12.64 180
Distant metastasisa
Absent 107 148.69 ± 6.36 160 0.010*
Present 15 192.17 ± 11.12 188

ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05

Conclusions

Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.